Agenus reports 72% of dMMR colon cancer patients cancer-free at surgery, 83% major pathologic response, after BOT+BAL in Phase 2 NEOASIS

Agenus reported that 72% of patients with locally advanced dMMR colon cancer had no cancer remaining at surgery and 83% achieved a major pathologic response following six weeks of BOT+BAL in its Phase 2 NEOASIS study, presented at ESMO 2026.

Detected & updated continuously · Source: Nebula